Ironwood Pharmaceuticals Stock News

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) reported Q4 FY21 sales of $117.1 million , compared to $116.7 million in Q4 FY20, beating the consensus of $109.87 million. Ironwood recorded $113.7 million in collaboration revenue in Q4 related to sales of LINZESS in the U.S., a 2.7% Y/Y increase, and $3.4 million in royalties and other revenue. Total … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Ironwood Pharmaceuticals press release (IRWD): Q4 Non-GAAP EPS of $0.27 misses by $0.07.Revenue of $117.13M (+0.4% Y/Y) beats by $6.96M.Guidance: FY22 The company expects the…

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open.The consensus EPS Estimate is $0.34 (-5.6% Y/Y) and…

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Is Ironwood Pharmaceuticals (IRWD) a great pick from the value investor's perspective right now? Read on to know more.

Is Ironwood Pharmaceuticals (IRWD) a great pick from the value investor's perspective right now? Read on to know more.

Gainers: Puma Biotechnology PBYI +16%, Marin Software (MRIN) +9%, Midland States Bancorp (MSBI) +6%, IDEAYA Biosciences (IDYA) +3%, Ironwood Pharmaceuticals (IRWD) +3%.Losers:…

Ironwood Pharmaceuticals <> sees FY21 LINZESS U.S. net sales to exceed $1B with LINZESS U.S. net sales growth, total Ironwood revenues, and Ironwood adjusted EBITDA to be at the…

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?